Search - tctmd.com

Displaying 161 - 180 of 588

Sort: Relevancy | Date

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

News Conference News EACTS 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

October 12, 2022

FFR/iFR No Help in CABG Surgery in SWEDEHEART Registry

News Conference News EACTS 2022

FFR/iFR No Help in CABG Surgery in SWEDEHEART Registry

Michael O'Riordan

October 07, 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

News Conference News TCT 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

Yael L. Maxwell

September 23, 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

News Conference News TCT 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

September 22, 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

News Conference News TCT 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

Yael L. Maxwell

September 21, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

TEER Linked to Better 1-Year Survival in Shock Patients With Significant MR

News Conference News TCT 2022

TEER Linked to Better 1-Year Survival in Shock Patients With Significant MR

Yael L. Maxwell

September 17, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope

News Conference News TCT 2022

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope

September 17, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

ESC Revamps Guidelines on Ventricular Arrhythmias, Sudden Cardiac Death

News Conference News ESC 2022

ESC Revamps Guidelines on Ventricular Arrhythmias, Sudden Cardiac Death

September 02, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Smartphone App Can Detect AF, Influence Care: eBRAVE-AF

News Conference News ESC 2022

Smartphone App Can Detect AF, Influence Care: eBRAVE-AF

August 30, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.